Perspectives on the Role of Histone Modification in Breast Cancer Progression and the Advanced Technological Tools to Study Epigenetic Determinants of Metastasis

Overview

Journal Front Genet

Date 2020 Nov 16

PMID 33193750

Citations 21

Authors

Jialang Zhuang

Qin Huo

Fan Yang

Ni Xie

Affiliations

Soon will be listed here.

Abstract

Metastasis is a complex process that involved in various genetic and epigenetic alterations during the progression of breast cancer. Recent evidences have indicated that the mutation in the genome sequence may not be the key factor for increasing metastatic potential. Epigenetic changes were revealed to be important for metastatic phenotypes transition with the development in understanding the epigenetic basis of breast cancer. Herein, we aim to present the potential epigenetic drivers that induce dysregulation of genes related to breast tumor growth and metastasis, with a particular focus on histone modification including histone acetylation and methylation. The pervasive role of major histone modification enzymes in cancer metastasis such as histone acetyltransferases (HAT), histone deacetylases (HDACs), DNA methyltransferases (DNMTs), and so on are demonstrated and further discussed. In addition, we summarize the recent advances of next-generation sequencing technologies and microfluidic-based devices for enhancing the study of epigenomic landscapes of breast cancer. This feature also introduces several important biotechnologists for identifying robust epigenetic biomarkers and enabling the translation of epigenetic analyses to the clinic. In summary, a comprehensive understanding of epigenetic determinants in metastasis will offer new insights of breast cancer progression and can be achieved in the near future with the development of innovative epigenomic mapping tools.

Citing Articles

Identifying Safeguards Disabled by Epstein-Barr Virus Infections in Genomes From Patients With Breast Cancer: Chromosomal Bioinformatics Analysis.

Friedenson B JMIRx Med. 2025; 6:e50712.

PMID: 39885374 PMC: 11796484. DOI: 10.2196/50712.

Immunohistochemical Profiling of Histone Modification Biomarkers Identifies Subtype-Specific Epigenetic Signatures and Potential Drug Targets in Breast Cancer.

Huo Z, Zhang S, Su G, Cai Y, Chen R, Jiang M Int J Mol Sci. 2025; 26(2).

PMID: 39859484 PMC: 11765579. DOI: 10.3390/ijms26020770.

Epigenetic Modulation of Estrogen Receptor Signaling in Ovarian Cancer.

Skrzypczak M, Wolinska E, Adaszek L, Ortmann O, Treeck O Int J Mol Sci. 2025; 26(1.

PMID: 39796024 PMC: 11720219. DOI: 10.3390/ijms26010166.

Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment.

Capatina A, Malcolm J, Stenning J, Moore R, Bridge K, Brackenbury W Front Cell Dev Biol. 2024; 12:1421629.

PMID: 39282472 PMC: 11392762. DOI: 10.3389/fcell.2024.1421629.

Bio-Pathological Functions of Posttranslational Modifications of Histological Biomarkers in Breast Cancer.

Neagu A, Josan C, Jayaweera T, Morrissiey H, Johnson K, Darie C Molecules. 2024; 29(17).

PMID: 39275004 PMC: 11397409. DOI: 10.3390/molecules29174156.

References

Shen Y, Wang P, Li Y, Ye F, Wang F, Wan X . miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer. 2013; 109(1):92-9. PMC: 3708577. DOI: 10.1038/bjc.2013.308. View

Li Y, Peng L, Seto E . Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7-HMGA2-Cyclin A2 Pathway. Mol Cell Biol. 2015; 35(20):3547-65. PMC: 4573710. DOI: 10.1128/MCB.00400-15. View

Grosselin K, Durand A, Marsolier J, Poitou A, Marangoni E, Nemati F . High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nat Genet. 2019; 51(6):1060-1066. DOI: 10.1038/s41588-019-0424-9. View

Voss A, Thomas T . Histone Lysine and Genomic Targets of Histone Acetyltransferases in Mammals. Bioessays. 2018; 40(10):e1800078. DOI: 10.1002/bies.201800078. View

Tang Z, Ding S, Huang H, Luo P, Qing B, Zhang S . HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8. Biol Chem. 2017; 398(12):1347-1356. DOI: 10.1515/hsz-2017-0155. View

Aljada A, Saleh A, Alkathiri M, Shamsa H, Al-Bawab A, Nasr A . Altered Sirtuin 7 Expression is Associated with Early Stage Breast Cancer. Breast Cancer (Auckl). 2015; 9:3-8. PMC: 4396534. DOI: 10.4137/BCBCR.S23156. View

Rauch T, Zhong X, Wu X, Wang M, Kernstine K, Wang Z . High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A. 2007; 105(1):252-7. PMC: 2224196. DOI: 10.1073/pnas.0710735105. View

Na T, Ka N, Rhee H, Kyeong D, Kim M, Seong J . Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma. Oncogene. 2016; 35(41):5435-5445. DOI: 10.1038/onc.2016.82. View

Karch K, Zee B, Garcia B . High resolution is not a strict requirement for characterization and quantification of histone post-translational modifications. J Proteome Res. 2014; 13(12):6152-9. PMC: 4261946. DOI: 10.1021/pr500902f. View

10.

Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R . Small molecule HDAC inhibitors: Promising agents for breast cancer treatment. Bioorg Chem. 2019; 91:103184. DOI: 10.1016/j.bioorg.2019.103184. View

11.

Hu Y, Petit S, Ficarro S, Toomire K, Xie A, Lim E . PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov. 2014; 4(12):1430-47. PMC: 4258125. DOI: 10.1158/2159-8290.CD-13-0891. View

12.

Zhou W, Du J, Jiang D, Wang X, Chen K, Tang H . microRNA‑183 is involved in the differentiation and regeneration of Notch signaling‑prohibited hair cells from mouse cochlea. Mol Med Rep. 2018; 18(2):1253-1262. PMC: 6072138. DOI: 10.3892/mmr.2018.9127. View

13.

Andersen G, Tost J . Circulating miRNAs as Biomarker in Cancer. Recent Results Cancer Res. 2019; 215:277-298. DOI: 10.1007/978-3-030-26439-0_15. View

14.

Thammaiah C, Jayaram S . Role of family microRNA in breast cancer. Noncoding RNA Res. 2018; 1(1):77-82. PMC: 6096426. DOI: 10.1016/j.ncrna.2016.10.003. View

15.

Cedar H, Bergman Y . Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009; 10(5):295-304. DOI: 10.1038/nrg2540. View

16.

Ediriweera M, Cho S . Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer. Pharmacol Ther. 2019; 206:107437. DOI: 10.1016/j.pharmthera.2019.107437. View

17.

Magerl C, Ellinger J, Braunschweig T, Kremmer E, Koch L, Holler T . H3K4 dimethylation in hepatocellular carcinoma is rare compared with other hepatobiliary and gastrointestinal carcinomas and correlates with expression of the methylase Ash2 and the demethylase LSD1. Hum Pathol. 2009; 41(2):181-9. DOI: 10.1016/j.humpath.2009.08.007. View

18.

Booth M, Marsico G, Bachman M, Beraldi D, Balasubramanian S . Quantitative sequencing of 5-formylcytosine in DNA at single-base resolution. Nat Chem. 2014; 6(5):435-40. PMC: 4188980. DOI: 10.1038/nchem.1893. View

19.

Cao C, Vasilatos S, Bhargava R, Fine J, Oesterreich S, Davidson N . Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression. Oncogene. 2016; 36(1):133-145. PMC: 5121103. DOI: 10.1038/onc.2016.186. View

20.

Gilpatrick T, Lee I, Graham J, Raimondeau E, Bowen R, Heron A . Targeted nanopore sequencing with Cas9-guided adapter ligation. Nat Biotechnol. 2020; 38(4):433-438. PMC: 7145730. DOI: 10.1038/s41587-020-0407-5. View